Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Items 601–700 of 1,004
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Gersh, B. J. (2010) · Yearbook of Cardiology · doi:10.1016/s0145-4145(09)79737-0 · Cited by 91
Raposeiras‐Roubín, S., Faxén, J., Íñiguez, A., Henriques, J. P. S., D’Ascenzo, F., Saucedo, J., Szummer, K. E., Jernberg, T., James, S. K., González‐Juanatey, J. R., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.103 · Cited by 98
The Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Cardiovascular Interventional Therapeutics (CVIT), Ozaki, Y., Katagiri, Y., Onuma, Y., Amano, T., Muramatsu, T., Kozuma, K., Otsuji, S., Ueno, T., Shiode, N., et al. (2018) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-018-0516-y · Cited by 90
“Overall mortality did not differ significantly between treatment groups [36].”
BackgroundRao, S. V., Dai, D. W. H., Subherwal, S., Weintraub, W. S., Brindis, R., Messenger, J. C., Lópes, R. D., & Peterson, E. D. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.05.010 · Cited by 93
Percutaneous coronary intervention in the elderly
Wang, T. Y., Gutiérrez, A., & Peterson, E. D. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.184 · Cited by 101
“A novel thienopyridine, prasugrel, was evaluated in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38)”
Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor
Dobesh, P. P. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.9.1089 · Cited by 91
Harold, J. G., Bass, T. A., Bashore, T. M., Brindis, R. G., Brush, J. E., Burke, J. A., DEHMER, G. J., Deychak, Y. A., Jneid, H. M., Jollis, J. G., et al. (2013) · Circulation · doi:10.1161/cir.0b013e318299cd8a · Cited by 102
Jeong, Y., Kim, I., Park, Y., Kang, M.-K., Koh, J., Hwang, S., Kwak, C. H., & Hwang, J. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.05.007 · Cited by 90
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 94
Self-citationBackhaus, T., Fach, A., Schmucker, J., Fiehn, E., Garstka, D., Stehmeier, J., Hambrecht, R., & Wienbergen, H. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-017-1192-0 · Cited by 92
Ducrocq, G., Amarenco, P., Labreuche, J., Alberts, M. J., Mas, J., Ohman, E. M., Goto, S., Lavallée, P. C., Bhatt, D. L., & Steg, P. G. (2012) · Circulation · doi:10.1161/circulationaha.112.141572 · Cited by 90
“In the TRITON-TIMI 38 trial, comparing prasugrel to clopidogrel in ACS patients treated with PCI, prasugrel reduced rates of ischemic events at a price of an increased risk of major bleeding in the overall population.(2) A post hoc analysis identified patients with previous stroke or TIA as deriving net clinical harm…”
MethodPokov, I., Kuliczkowski, W., Chesebro, J. H., Badimón, J. J., & Serebruany, V. L. (2008) · Thrombosis and Haemostasis · doi:10.1160/th08-03-0136 · Cited by 90
Postoperative Critical Care of the Adult Cardiac Surgical Patient: Part II
Stephens, R. S., & Whitman, G. J. R. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000001171 · Cited by 108
Aradi, D., Tornyos, A., Pintér, T., Vorobcsuk, A., Kónyi, A., Faluközy, J., Veress, G., Magyari, B., Horváth, I., & Komócsi, A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.12.023 · Cited by 99
“clopidogrel in patients with ACS (5,6), the higher risk of major bleeding together with the higher treatment costs limit their use in routine practice.”
InfluentialGenetic determinants of platelet response to clopidogrel
Kubica, A., Koziński, M., Grześk, G., Fabiszak, T., Navarese, E. P., & Goch, A. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0611-8 · Cited by 89
“Well known TRITON-TIMI 38 study showed significantly better results in the prasugrel group as compared to the whole group of patients treated with clopidogrel in terms of primary efficacy outcome of cardiovascular death, myocardial infarction, and stroke [35].”
ResultGaudino, M. F. L., Angiolillo, D. J., Franco, A. D., Capodanno, D., Bakaeen, F. G., Farkouh, M. E., Fremes, S. E., Holmes, D. R., Girardi, L. N., Nakamura, S., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013032 · Cited by 99
“Importantly, prasugrel may increase the risk of fatal and intracranial bleeding in patients with prior stroke or transient ischemic attack, representing an absolute contraindication for its use.(90)”
BackgroundPlatelets and Metastasis: New Implications of an Old Interplay
Lucotti, S., & Muschel, R. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01350 · Cited by 96
“Despite promising preclinical data, the ADP P2Y12 receptor antagonist prasugrel (TRITON-TIMI 38 trial) (281, 282) and the P2Y12 inhibitors thienopyridines (clopidogrel and prasugrel) (283) increased the incidence of newly diagnosed solid cancers and the risk of cancerrelated death.”
BackgroundPrasugrel in Clinical Practice
Bhatt, D. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0806848 · Cited by 89
Amin, A. P., Bachuwar, A., Reid, K. J., Chhatriwalla, A. K., Salisbury, A. C., Yeh, R. W., Kosiborod, M., Wang, T. Y., Alexander, K. P., GOSCH, K. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.044 · Cited by 89
A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?
Gargiulo, G., Windecker, S., Vranckx, P., Gibson, C. M., Mehran, R., & Valgimigli, M. (2016) · Circulation · doi:10.1161/circulationaha.116.023952 · Cited by 97
Self-citationStone, S. G., Serrao, G. W., Mehran, R., Tomey, M. I., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., Brodie, B. R., Dudek, D., Möckel, M., et al. (2014) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001360 · Cited by 93
Perioperative Management of Patients With Drug-Eluting Stents
Abualsaud, A. O., & Eisenberg, M. J. (2010) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.11.017 · Cited by 88
Management and Prevention of Saphenous Vein Graft Failure: A Review
McKavanagh, P., Yanagawa, B., Zawadowski, G. M., & Cheema, A. N. (2017) · Cardiology and Therapy · doi:10.1007/s40119-017-0094-6 · Cited by 96
Wang, T. Y., Kaltenbach, L. A., Cannon, C. P., Fonarow, G. C., Choudhry, N. K., Henry, T. D., Cohen, D. J., Bhandary, D., Khan, N. D., Anstrom, K. J., et al. (2019) · JAMA · doi:10.1001/jama.2018.19791 · Cited by 89
Samuel, M., Tardif, J., Khairy, P., Roubille, F., Waters, D. D., Grégoire, J. C., Pinto, F. J., Maggioni, A. P., Díaz, R., Berry, C., et al. (2020) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaa045 · Cited by 91
“Infarction 38 (TRITON-TIMI 38) (24) and a subgroup analysis of Clopidogrel for High”
BackgroundVoluntary exploratory data submissions to the US FDA and the EMA: experience and impact
Goodsaid, F. M., Amur, S., Aubrecht, J., Burczynski, M. E., Carl, K., Catalano, J. G., Charlab, R., Close, S. L., Cornu-Artis, C., Essioux, L., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3116 · Cited by 88
“Prasugrel biomarkers at Lilly An NDA filed by Eli Lilly and Company (Lilly) for prasugrel (Effient”
Sousa‐Uva, M., Storey, R. F., Huber, K., Falk, V., Leite-Moreira, A. F., Amour, J., Al‐Attar, N., Ascione, R., Taggart, D. P., Collet, J. ‐., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu158 · Cited by 91
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Collet, J., Silvain, J., Landivier, A., Tanguy, M., Cayla, G., Bellemain-Appaix, A., Vignolles, N., Gallier, S., Beygui, F., Peña, A., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.776757 · Cited by 87
Self-citationMyocardial infarction in the elderly.
Carro, A., & Kaski, J. C. (2011) · Europe PMC (PubMed Central) · Cited by 101
Fitchett, D., Eikelboom, J., Fremes, S., Mazer, D., Singh, S. K., Bittira, B., Brister, S., Graham, J., Gupta, M., Karkouti, K., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70527-6 · Cited by 88
“The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel – Thrombolysis In Myocardial Infarction (TRITONTIMI 38) study (71) showed that prasugrel compared with clopidogrel, administered at the time of PCI in patients with a recent ACS, resulted in a 19% reduction of deat…”
MethodVranckx, P., Lewalter, T., Valgimigli, M., Tijssen, J. G. P., Reimitz, P., Eckardt, L., Lanz, H., Zierhut, W., Smolnik, R., & Goette, A. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.10.009 · Cited by 91
Fanaroff, A. C., Cyr, D. D., Neely, M. L., Bakal, J. A., White, H. D., Fox, K. A. A., Armstrong, P. W., Lópes, R. D., Ohman, E. M., & Roe, M. T. (2018) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.118.004755 · Cited by 93
Recent developments in clopidogrel pharmacology and their relation to clinical outcomes
Gurbel, P. A., Antonino, M. J., & Tantry, U. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903107772 · Cited by 89
Hankey, G. J., & Eikelboom, J. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70038-7 · Cited by 94
Zhang, P., Gruber, A., Kasuda, S., Kimmelstiel, C. D., O’Callaghan, K., Cox, D. H., Bohm, A., Baleja, J., Covic, L., & Kuliopulos, A. (2012) · Circulation · doi:10.1161/circulationaha.112.091918 · Cited by 88
The coagulation system in atherothrombosis: Implications for new therapeutic strategies
Olie, R. H., van der Meijden, P. E. J., & Cate, H. T. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12080 · Cited by 97
Platelet function testing and risk of bleeding complications
Ferreiro, J. L., Sibbing, D., & Angiolillo, D. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0799 · Cited by 104
Bernlochner, I., Goedel, A., Plischke, C., Schüpke, S., Haller, B., Schulz, C., Mayer, K., Morath, T., Braun, S., Schunkert, H., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv326 · Cited by 85
Pathogenesis of Aspirin-Exacerbated Respiratory Disease and Reactions
Laidlaw, T. M., & Boyce, J. A. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.11.006 · Cited by 85
Costa, F., Vranckx, P., Leonardi, S., Moscarella, E., Andò, G., Calabrò, P., Oreto, G., Zijlstra, F., & Valgimigli, M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv038 · Cited by 86
Kwok, C. S., Wong, C. W., Kontopantelis, E., Barac, A., Brown, S.-A. N., Velagapudi, P., Hilliard, A. A., Bharadwaj, A. S., Alraies, M. C., Mohamed, M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1032 · Cited by 88
Lindsey, J. B., Marso, S. P., Pencina, M. J., Stolker, J. M., Kennedy, K. F., Rihal, C. S., Barsness, G. W., Piana, R. N., Goldberg, S. L., Cutlip, D. E., et al. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.09.002 · Cited by 85
Généreux, P., Rutledge, D. R., Palmerini, T., Caixeta, A. M., Kedhi, E., Hermiller, J. B., Wang, J., Krucoff, M. W., Jones-McMeans, J. M., Sudhir, K., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.114.001362 · Cited by 86
An overview of PCI in the very elderly.
Shanmugam, V. B., Harper, R., Meredith, I. T., Malaiapan, Y. R., & Psaltis, P. J. (2015) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2015.02.012 · Cited by 129
Erlinge, D., ten Berg, J. M., Foley, D., Angiolillo, D. J., Wagner, H., Brown, P. B., Zhou, C., Luo, J., Jakubowski, J. A., Moser, B. A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.964 · Cited by 84
“The TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction) study demonstrated significantly reduced rates of ischemic events for prasugrel compared with clopidogrel for the composite efficacy endpoint of cardiovascular…”
BackgroundSmith, J. G., Wieloch, M., Koul, S. M., Braun, O. Ö., Lumsden, J., Rydell, E., Öhman, J. N., Scherstén, F., Svensson, P. J., & van der Pals, J. (2012) · EuroIntervention · doi:10.4244/eijv8i6a105 · Cited by 89
Platelets Are at the Nexus of Vascular Diseases
Lebas, H., Yahiaoui, K., Martos, R., & Boulaftali, Y. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00132 · Cited by 91
Wrishko, R. E., Ernest, C. S., Small, D. S., Li, Y. G., Weerakkody, G. J., Riesmeyer, J., Macias, W. L., Rohatagi, S., Salazar, D. E., Antman, E. M., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337942 · Cited by 84
“Briefly, TRITONTIMI 38 was a phase III, multicenter, randomized, parallel-group, double-blind, double-dummy, activecontrolled study.(3) The study population included patients with ACS (patients with STEMI undergoing primary PCI or after medical stabilization and patients with UA/NSTEMI with TIMI risk score ≥3)(19) who…”
BackgroundMethodResultInfluentialSelf-citationChronic stable coronary artery disease: drugs vs. revascularization
Simoons, M. L., & Windecker, S. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp605 · Cited by 97
Washam, J. B., Herzog, C. A., Beitelshees, A. L., Cohen, M. G., Henry, T. D., Kapur, N. K., Mega, J. L., Menon, V., Page, R. L., II, & Newby, L. K. (2015) · Circulation · doi:10.1161/cir.0000000000000183 · Cited by 96
Platelet receptors as therapeutic targets: Past, present and future
Jamasbi, J., Ayabe, K., Goto, S., Nieswandt, B., Peter, K., & Siess, W. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-12-0911 · Cited by 87
“In patients with acute coronary syndrome, 60 mg loading dose followed by a 20 mg maintenance dose of prasugrel is approved in the majority of countries in the world including China and Korea except for Japan due to the results of global TRITON TIMI 38 trials (134).”
BackgroundReese, E. S., Mullins, C. D., Beitelshees, A. L., & Onukwugha, E. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01048 · Cited by 83
“The study found that prasugrel was associated with a reduction in the primary end point (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) but with an increased risk of fatal and major bleeding events.(12) Prasugrel is also a prodrug, but its activation occurs in a single, efficient…”
BackgroundMethodMagnani, G., Storey, R. F., Steg, P. G., Bhatt, D. L., Cohen, M. C., Kuder, J., Im, K., Aylward, P. E., Ardissino, D., Isaza, D., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv482 · Cited by 91
“Previous studies have described an inverse relationship between eGFR and ischaemic and bleeding events in patients with a recent MI [4, 9, 18].”
BackgroundMethodInfluentialSelf-citationAntiplatelet Use in Ischemic Stroke
Kamarova, M., Baig, S. S., Patel, H., Monks, K. R., Wasay, M., Ali, A., Redgrave, J. N. E., Majid, A., & Bell, S. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211073009 · Cited by 107
Antiplatelet therapy: new pharmacological agents and changing paradigms
Capodanno, D., Ferreiro, J. L., & Angiolillo, D. J. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12219 · Cited by 94
Stachon, P., Geis, S., Peikert, A., Heidenreich, A., Michel, N. A., Ünal, F., Hoppe, N., Dufner, B., Schulte, L., Marchini, T., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.307397 · Cited by 83
Drug-Eluting Stent Thrombosis in Routine Clinical Practice
Lasala, J. M., Cox, D. A., Dobies, D., Baran, K. W., Bachinsky, W., Rogers, E. W., Breall, J. A., Lewis, D. H., Song, A., Starzyk, R. M., et al. (2009) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.109.852178.109.852178 · Cited by 88
Bagai, A., Peterson, E. D., Honeycutt, E. F., Effron, M. B., Cohen, D. J., Goodman, S. G., Anstrom, K. J., Gupta, A., Messenger, J. C., & Wang, T. Y. (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614564082 · Cited by 85
Bergmeijer, T. O., Janssen, P. W. A., Schipper, J., Qaderdan, K., Ishak, M., Ruitenbeek, R. S., Asselbergs, F. W., Hof, A. W. J. V. ’., Dewilde, W. J. M., Spanó, F., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.006 · Cited by 89
Verma, S., Goodman, S. G., Mehta, S. R., Latter, D. A., Ruel, M., Gupta, M., Yanagawa, B., Al-Omran, M. A., Gupta, N., Teoh, H., et al. (2015) · BMC Surgery · doi:10.1186/s12893-015-0096-z · Cited by 85
“Of the ACS trials, 2 compared clopidogrel plus ASA to ASA alone [3, 20], and 2 compared higher intensity dual anti-platelet therapy with either ticagrelor [5] or prasugrel [4] plus ASA vs clopidogrel plus ASA.”
MethodInfluentialAssociation of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention
Chichareon, P., Modolo, R., Kerkmeijer, L. S. M., Tomaniak, M., Kogame, N., Takahashi, K., Chang, C., Komiyama, H., Moccetti, T., Talwar, S., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4296 · Cited by 82
Husted, S., James, S. K., Bach, R. G., Becker, R. C., Budaj, A., Heras, M., Himmelmänn, A., Horrow, J. C., Katus, H. A., Lassila, R., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu075 · Cited by 88
Silvain, J., Peña, A., Cayla, G., Brieger, D. B., Bellemain-Appaix, A., Chastre, T., Vignalou, J.-B., Beygui, F., Barthélémy, O., Collet, J. ‐., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq209 · Cited by 85
“complications with frequent utilization of red blood cell (RBC) transfusion.(1,2) The true incidence of bleeding varies in reported”
BackgroundSelf-citationPlatelet Biology and Response to Antiplatelet Therapy in Women
Wang, T. Y., Angiolillo, D. J., Cushman, M., Sabatine, M. S., Bray, P. F., Smyth, S. S., Dauerman, H. L., French, P. A., & Becker, R. C. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.075 · Cited by 86
Lau, W. C., Welch, T. D., Shields, T. A., Rubenfire, M., Tantry, U. S., & Gurbel, P. A. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181ffe8d0 · Cited by 82
“Increasing the dose may have an economical impact, whereas the use of prasugrel and ticagrelor has been highlighted with greater lifethreatening bleeding and dyspnea and ventricular pauses, respectively.(23,24) We are introducing a novel approach to overcome clopidogrel hyporesponsiveness in post-PCI patients with SJW…”
BackgroundProjecting future drug expenditures—2012
Hoffman, J. M., Li, E., Doloresco, F., Matusiak, L. M., Hunkler, R. J., Shah, N. D., Vermeulen, L. C., & Schumock, G. T. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110697 · Cited by 87
Cuisset, T., Frère, C., Quilici, J., Morange, P., Camoin‐Jau, L., Bali, L., Lambert, M., Juhan-Vague, I., Alessi, M., & Bonnet, J. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.04.003 · Cited by 84
“new oral thienopyridine, the prasugrel over clopidogrel [28] and more recently, clinical superiority was confirmed in a large randomized trial [29].”
BackgroundChyrchel, B., Totoń‐Żurańska, J., Kruszelnicka, O., Chyrchel, M., Mielecki, W., Kołton‐Wróż, M., Wołkow, P. P., & Surdacki, A. (2014) · Platelets · doi:10.3109/09537104.2014.974527 · Cited by 83
“However, this assumption appears likely because for standard plasma Zhang et al. [8] obtained results similar to Shi et al. [7] in a comparable group of patients with non-ST-elevation ACS.”
BackgroundResultInfluentialEvolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy
Moon, J. Y., Franchi, F., Rollini, F., & Angiolillo, D. J. (2017) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2017.12.004 · Cited by 81
Komócsi, A., Vorobcsuk, A., Kehl, D., & Aradi, D. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.4026 · Cited by 83
Leonardi, S., Rao, S. V., Harrington, R. A., Bhatt, D. L., Gibson, C. M., Roe, M. T., Kochman, J., Huber, K., Zeymer, U., Madan, M., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.04.008 · Cited by 79
Self-citationVaglio, S., Prisco, D., Biancofiore, G., Rafanelli, D., Antonioli, P., Lisanti, M., Andreani, L., Basso, L., Velati, C., Grazzini, G., et al. (2016) · PubMed · doi:10.2450/2015.0172-15 · Cited by 98
Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors
Kubica, J., Kubica, A., Jilma, B., Adamski, P., Hobl, E., Navarese, E. P., Siller-Matula, J. M., Dąbrowska, A. M., Fabiszak, T., Koziński, M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.077 · Cited by 86
Leonardi, S., Mahaffey, K. W., White, H. D., Gibson, C. M., Stone, G. W., Steg, P. G., Hamm, C. W., Price, M. J., Todd, M., Dietrich, M., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.02.018 · Cited by 79
Self-citationBaber, U., Mehran, R., Kirtane, A. J., Gurbel, P. A., Christodoulidis, G., Maehara, A., Witzenbichler, B., Weisz, G., Rinaldi, M., Metzger, D. C., et al. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.115.001683 · Cited by 85
ADP Platelet Hyperreactivity Predicts Cardiovascular Disease in the FHS (Framingham Heart Study)
Puurunen, M. K., Hwang, S., Larson, M. G., Vasan, R. S., O’Donnell, C. J., Tofler, G. H., & Johnson, A. D. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008522 · Cited by 81
Lee, C. R., Sriramoju, V., Cervantes, A., Howell, L. A., Varunok, N., Madan, S., Hamrick, K., Polasek, M. J., Lee, J. A., Clarke, M. M., et al. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.117.002069 · Cited by 80
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
Costa, F., & Valgimigli, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1508692 · Cited by 85
Siller-Matula, J. M., Huber, K., Christ, G., Schrör, K., Kubica, J., Herkner, H., & Jilma, B. (2010) · Heart · doi:10.1136/hrt.2010.195438 · Cited by 79
“The approved loading dose of clopidogrel is 300 mg.20 Increasing evidence, however, indicated that higher clopidogrel doses improve the antiplatelet effect and patients’ outcome, which is due to the higher absolute level of platelet inhibition and more rapid onset of action.4 21 22 The recent STEMI guidelines of the E…”
BackgroundInfluentialFrailty is a short-term prognostic marker in acute coronary syndrome of elderly patients
Salinas, G. L. A., Sanmartín, M., Izco, M. P., Martín‐Asenjo, R., Mayoral, A. R., Ramos, L. S., Martín, D. M., López, A. C., Mena, M., & Gómez, J. L. Z. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616644909 · Cited by 96
Kaikita, K., Hosokawa, K., Dahlen, J. R., & Tsujita, K. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1693411 · Cited by 87
Gender-based differences in platelet function and platelet reactivity to P2Y12 inhibitors
Ranucci, M., Aloisio, T., Dedda, U. D., Menicanti, L., Vincentiis, C. D., & Baryshnikova, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225771 · Cited by 87
“In patients under double anti-platelet therapy (DAPT) the interaction between gender and efficacy was absent [11, 12] or only demonstrated a trend towards a lower efficacy in women [13].”
BackgroundPlatelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy
Baaten, C. C. F. M. J., Schröer, J. R., Floege, J., Marx, N., Jankowski, J., Berger, M., & Noels, H. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04100321 · Cited by 94
Alexopoulos, D., Panagiotou, A., Xanthopoulou, I., Komninakis, D., Kassimis, G., Davlouros, P. A., Fourtounas, C., & Goumenos, D. S. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04531.x · Cited by 80
van Giezen, J. J. J., Berntsson, P., Zachrisson, H., & Björkman, J. (2009) · Thrombosis Research · doi:10.1016/j.thromres.2009.06.029 · Cited by 79
“acute coronary syndromes (ACS) with scheduled percutaneous coronary intervention, prasugrel (60-mg load and 10-mg maintenance) compared with clopidogrel (300-mg load and 75-mg maintenance) treatment was associated with a significant reduction in the primary endpoint (death from cardiovascular causes, nonfatal myocardi…”
Dipyridamole, cerebrovascular disease, and the vasculature
Chakrabarti, S., & Freedman, J. E. (2008) · Vascular Pharmacology · doi:10.1016/j.vph.2007.12.004 · Cited by 79
Aronow, H. D., Steinhubl, S. R., Brennan, D. M., Berger, P. B., & Topol, E. J. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.09.011 · Cited by 79
Impact of race and gender on antithrombotic therapy
Capodanno, D., & Angiolillo, D. J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-04-0232 · Cited by 83
for the GRACE Investigators, Fox, K. A. A., Anderson, F. A., Goodman, S. G., Steg, P. G., Pieper, K. S., Quill, A., & Gore, J. M. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1302 · Cited by 89
Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD
Müller, K., Chatterjee, M., Rath, D., & Geisler, T. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0947 · Cited by 90
“Another retrospective cohort study of 3,137 patients with ACS and post-discharge clopidogrel treatment reported a clustering of adverse events in the initial 90 days after clopidogrel discontinuation among both medically treated and PCI-treated patients, supporting the possibility of a clopidogrel rebound effect (146).”
BackgroundInfluentialManchikanti, L., Falco, F. J. E., Benyamin, R. M., Caraway, D. L., Kaye, A. D., Helm, S., Wargo, B. W., Hansen, H. C., Parr, A. T., Singh, V., et al. (2013) · Pain Physician · doi:10.36076/ppj.2013/16/se216 · Cited by 82
Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis
Pilgrim, T., Stortecky, S., Luterbacher, F., Windecker, S., & Wenaweser, P. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0842-3 · Cited by 78
“Bleeding complications have been associated with adverse clinical outcome in patients undergoing percutaneous coronary interventions for treatment of coronary artery disease, and are related to access site [3], vascular access sheath diameter, as well as antiplatelet and antithrombotic regimen [4, 5].”
BackgroundGuía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 123
Platelet-Mediated Thrombosis: From Bench to Bedside
Gurbel, P. A., Jeong, Y.-H., Navarese, E. P., & Tantry, U. S. (2016) · Circulation Research · doi:10.1161/circresaha.115.307016 · Cited by 78
Acute Coronary Syndromes: Differences in Men and Women
Kawamoto, K. R., Davis, M. B., & Duvernoy, C. S. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0629-7 · Cited by 93
Antiplatelet Therapy in Flow Diversion
Tonetti, D. A., Jankowitz, B. T., & Gross, B. A. (2019) · Neurosurgery · doi:10.1093/neuros/nyz391 · Cited by 78
Hoenig, M. R., Aroney, C. N., & Scott, I. A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004815.pub3 · Cited by 79
Koul, S. M., Smith, J. G., Scherstén, F., James, S. K., Lagerqvist, B., & Erlinge, D. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr202 · Cited by 85
“However, the results are in accordance with the TRITON trial where underweight patients were neutral in net clinical benefit.(9)”
ResultSimonsson, M., Wallentin, L. C., Alfredsson, J., Erlinge, D., Ängerud, K. H., Hofmann, R., Kellerth, T., Lindhagen, L., Ravn‐Fischer, A., Szummer, K. E., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz593 · Cited by 81
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.